Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Jun 3. doi: 10.1056/NEJMoa1803675. [Epub ahead of print]

2.

Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.

Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V.

J Neurooncol. 2018 Jun;138(2):369-382. doi: 10.1007/s11060-018-2805-9. Epub 2018 Feb 27.

PMID:
29488184
3.

Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer.

Chiba A, Raman R, Thomas A, Lamy PJ, Viala M, Pouderoux S, Mott SL, Schroeder MC, Thezenas S, Jacot W.

Clin Breast Cancer. 2018 Apr;18(2):144-149. doi: 10.1016/j.clbc.2017.12.001. Epub 2017 Dec 11.

PMID:
29290565
4.

MRI-based score to predict surgical difficulty in patients with rectal cancer.

Escal L, Nougaret S, Guiu B, Bertrand MM, de Forges H, Tetreau R, Thézenas S, Rouanet P.

Br J Surg. 2018 Jan;105(1):140-146. doi: 10.1002/bjs.10642. Epub 2017 Oct 31.

PMID:
29088504
5.

Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country.

Senesse P, Isambert A, Janiszewski C, Fiore S, Flori N, Poujol S, Arroyo E, Courraud J, Guillaumon V, Mathieu-Daudé H, Colasse S, Baracos V, de Forges H, Thezenas S.

J Pain Symptom Manage. 2017 Sep;54(3):387-393.e3. doi: 10.1016/j.jpainsymman.2017.01.010. Epub 2017 Aug 1.

PMID:
28778558
6.

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Viala M, Alexandre M, Thezenas S, Lamy PJ, Maran-Gonzalez A, Gutowski M, Colombo PE, Romieu G, Jacot W, Guiu S.

Breast Cancer Res Treat. 2017 Oct;165(3):611-621. doi: 10.1007/s10549-017-4373-7. Epub 2017 Jul 6.

PMID:
28685212
7.

SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization.

Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, Gylling HM, Maglieri G, Rundsten CF, Seemann SE, Rapin N, Thézenas S, Vang S, Ørntoft T, Andersen CL, Pedersen JS, Lund AH.

Nat Commun. 2016 Dec 22;7:13875. doi: 10.1038/ncomms13875.

8.

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W.

Int J Cancer. 2016 Nov 15;139(10):2299-311. doi: 10.1002/ijc.30290. Epub 2016 Aug 6.

9.

Meal context and food preferences in cancer patients: results from a French self-report survey.

Guerdoux-Ninot E, Kilgour RD, Janiszewski C, Jarlier M, Meuric J, Poirée B, Buzzo S, Ninot G, Courraud J, Wismer W, Thezenas S, Senesse P.

Springerplus. 2016 Jun 21;5(1):810. doi: 10.1186/s40064-016-2538-1. eCollection 2016.

10.

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W.

BMC Cancer. 2016 Jul 7;16:428. doi: 10.1186/s12885-016-2448-1.

11.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F.

Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.

PMID:
27167986
12.

Bone metastases in gastrointestinal cancer.

Portales F, Thézenas S, Samalin E, Assenat E, Mazard T, Ychou M.

Clin Exp Metastasis. 2015 Jan;32(1):7-14. doi: 10.1007/s10585-014-9686-x. Epub 2014 Nov 9.

PMID:
25381591
13.

Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?

Gioulbasanis I, Martin L, Baracos VE, Thézénas S, Koinis F, Senesse P.

Ann Oncol. 2015 Jan;26(1):217-21. doi: 10.1093/annonc/mdu501. Epub 2014 Oct 30.

PMID:
25361991
14.

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer.

Saadoun H, Lamy PJ, Thezenas S, Pouderoux S, Bibeau F, Montels F, Romieu G, Colombo PE, Gutowski M, Jacot W.

Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177.

PMID:
24490606
15.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.

Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T.

Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9.

16.

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer.

El Demery M, Demirdjian-Sarkissian G, Thezenas S, Jacot W, Laghzali Y, Darbouret B, Culine S, Rebillard X, Lamy PJ.

Clin Transl Med. 2014 Oct 28;3:31. doi: 10.1186/s40169-014-0031-4. eCollection 2014.

17.

Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.

Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853-9. doi: 10.1016/j.ijrobp.2013.11.016. Epub 2013 Dec 21.

18.

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.

Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ.

BMC Cancer. 2013 Nov 5;13:523. doi: 10.1186/1471-2407-13-523.

19.

A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E.

Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17.

PMID:
23955585
20.

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8. doi: 10.1016/j.breast.2013.05.011. Epub 2013 Jul 3.

PMID:
23831232
21.

Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification.

Durigova A, Lamy PJ, Thezenas S, Pouderoux S, Montels F, Romieu G, Gutowski M, Jacot W.

Clin Chem Lab Med. 2013 Sep;51(9):1833-41. doi: 10.1515/cclm-2013-0031.

PMID:
23787470
22.

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferreri JM, Jacot W.

BMC Cancer. 2013 Feb 8;13:70. doi: 10.1186/1471-2407-13-70.

23.

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.

Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse JP, Romieu G, Lamy PJ.

Breast Cancer Res Treat. 2012 Jul;134(2):709-17. doi: 10.1007/s10549-012-2084-7. Epub 2012 May 6.

PMID:
22562178
24.

Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E.

World J Gastroenterol. 2012 Mar 28;18(12):1357-64. doi: 10.3748/wjg.v18.i12.1357.

25.

Immunonutrition before and during radiochemotherapy: improvement of inflammatory parameters in head and neck cancer patients.

Machon C, Thezenas S, Dupuy AM, Assenat E, Michel F, Mas E, Senesse P, Cristol JP.

Support Care Cancer. 2012 Dec;20(12):3129-35. doi: 10.1007/s00520-012-1444-5. Epub 2012 Mar 28.

PMID:
22453793
26.

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.

Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy PJ.

Breast Cancer Res. 2011;13(6):R133. doi: 10.1186/bcr3079. Epub 2011 Dec 22.

27.

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.

Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse JP, Portales F, Samalin E, Assenat E.

Cancer Chemother Pharmacol. 2012 Mar;69(3):807-14. doi: 10.1007/s00280-011-1764-z. Epub 2011 Oct 30.

PMID:
22037922
28.

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.

Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M.

Oncologist. 2011;16(11):1557-64. doi: 10.1634/theoncologist.2011-0141. Epub 2011 Oct 20.

29.

Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.

Demery ME, Thézenas S, Pouessel D, Culine S.

Anticancer Drugs. 2012 Feb;23(2):143-8. doi: 10.1097/CAD.0b013e32834c2ab6. Review.

PMID:
21934599
30.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M.

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54.

PMID:
21634054
31.

Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy.

Assenat E, Thezenas S, Flori N, Pere-Charlier N, Garrel R, Serre A, Azria D, Senesse P.

J Pain Symptom Manage. 2011 Oct;42(4):548-56. doi: 10.1016/j.jpainsymman.2011.01.009. Epub 2011 Apr 7.

PMID:
21477980
32.

A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer.

Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, Bibeau F, Boissière-Michot F, Thezenas S, Cellier D, Azria D, Rouanet P, Senesse P, Ychou M, Lopez-Crapez E.

Pharmacogenomics J. 2011 Dec;11(6):437-43. doi: 10.1038/tpj.2010.62. Epub 2010 Jul 20.

PMID:
20644561
33.

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.

Jacot W, Gerlotto-Borne MC, Thezenas S, Pouderoux S, Poujol S, About M, Romieu G.

BMC Cancer. 2010 Jun 4;10:257. doi: 10.1186/1471-2407-10-257.

34.

Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.

Duffour J, Thézenas S, Dereure O, Garcin A, Caron J, Samalin E, Portales F, Fiess C, Chalbos P, Gestin-Boyer C, Ychou M, Guillot B.

Eur J Cancer. 2010 Dec;46(18):3169-74. doi: 10.1016/j.ejca.2010.03.008. Epub 2010 Apr 21.

PMID:
20417092
35.

CIP2A is associated with human breast cancer aggressivity.

Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J.

Clin Cancer Res. 2009 Aug 15;15(16):5092-100. doi: 10.1158/1078-0432.CCR-08-3283. Epub 2009 Aug 11.

36.

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A.

Ann Oncol. 2009 Dec;20(12):1964-70. doi: 10.1093/annonc/mdp236. Epub 2009 Jun 30.

PMID:
19567451
37.

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.

J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.

PMID:
19164213
38.

Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.

Granci V, Bibeau F, Kramar A, Boissière-Michot F, Thézénas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M.

Eur J Cancer. 2008 Oct;44(15):2312-8. doi: 10.1016/j.ejca.2008.06.042. Epub 2008 Aug 26.

39.

A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.

Bécouarn Y, Senesse P, Thézenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C, Ychou M; Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.

Ann Oncol. 2007 Dec;18(12):2000-5. Epub 2007 Sep 4.

PMID:
17785765
40.

[Positive sentinel node biopsy in breast cancer: is axillary surgery necessary in all cases?].

Trentini F, Saint-Aubert B, Quenet F, Gutowski M, Bibeau F, Simony-Lafontaine J, Chateau MC, Pourquier D, Eslimani M, Delfour C, Gourgou S, Thezenas S, Rouanet P.

Bull Cancer. 2007 Jul;94(7):700-4. French.

41.

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.

Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, Azria D.

Clin Cancer Res. 2007 Jun 1;13(11):3356-62.

42.

Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer.

Ho-Pun-Cheung A, Assenat E, Thezenas S, Bibeau F, Rouanet P, Azria D, Cellier D, Grenier J, Ychou M, Senesse P, Lopez-Crapez E.

Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1094-101. Epub 2007 Mar 29.

PMID:
17398034
43.

The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower-third rectal adenocarcinoma.

Assenat E, Thézenas S, Samalin E, Bibeau F, Portales F, Azria D, Quenet F, Rouanet P, Saint Aubert B, Senesse P.

Endoscopy. 2007 Apr;39(4):309-13. Epub 2007 Mar 13.

PMID:
17354183
44.

Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis.

Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H.

Int J Cancer. 2007 Jan 15;120(2):224-9.

45.

Hepatic metastases from carcinomas of unknown primary site.

Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M.

Gastroenterol Clin Biol. 2005 Dec;29(12):1224-32.

46.

Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results.

Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P, Fenoglietto P, Ailleres N, Dubois JB.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1410-5. Epub 2006 Jan 25.

PMID:
16442241
47.

[Sun exposure and sun protection behavior and attitudes among the French population].

Stoebner-Delbarre A, Thezenas S, Kuntz C, Nguyen C, Giordanella JP, Sancho-Garnier H, Guillot B; Groupe EPI-CES.

Ann Dermatol Venereol. 2005 Aug-Sep;132(8-9 Pt 1):652-7. French.

PMID:
16230914
48.

Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.

Solassol I, Caumette L, Bressolle F, Garcia F, Thézenas S, Astre C, Culine S, Coulouma R, Pinguet F.

Oncol Rep. 2005 Oct;14(4):1029-36.

PMID:
16142368
49.

Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.

Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S.

BMC Cancer. 2005 Jun 20;5:62.

50.

p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.

Lopez-Crapez E, Bibeau F, Thézenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P.

Br J Cancer. 2005 Jun 20;92(12):2114-21.

Supplemental Content

Loading ...
Support Center